Matritech NMP22 Assay Approvable As Adjunct Bladder Cancer Diagnostic
This article was originally published in The Gray Sheet
Executive SummaryLabeling for Matritech's NMP22 urine assay should state that the product is for use "in conjunction with and not in lieu of" standard bladder cancer detection procedures, FDA's Immunology Devices Panel concluded Dec. 13.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.